Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals Enterprise Value : 1.021B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 1.021B |
| November 05, 2026 | 1.006B |
| November 04, 2026 | 1.103B |
| November 03, 2026 | 1.448B |
| November 02, 2026 | 1.341B |
| October 30, 2026 | 1.391B |
| October 29, 2026 | 1.436B |
| October 28, 2026 | 1.451B |
| October 27, 2026 | 1.394B |
| October 26, 2026 | 1.352B |
| October 23, 2026 | 1.368B |
| October 22, 2026 | 1.383B |
| October 21, 2026 | 1.346B |
| October 20, 2026 | 1.355B |
| October 19, 2026 | 1.340B |
| October 16, 2026 | 1.323B |
| October 15, 2026 | 1.391B |
| October 14, 2026 | 1.380B |
| October 13, 2026 | 1.418B |
| October 12, 2026 | 1.652B |
| October 09, 2026 | 1.691B |
| October 08, 2026 | 1.683B |
| October 07, 2026 | 1.695B |
| October 06, 2026 | 1.725B |
| October 05, 2026 | 1.767B |
| Date | Value |
|---|---|
| October 02, 2026 | 1.746B |
| October 01, 2026 | 1.802B |
| September 30, 2026 | 1.854B |
| September 29, 2026 | 1.667B |
| September 28, 2026 | 1.634B |
| September 25, 2026 | 1.664B |
| September 24, 2026 | 1.644B |
| September 23, 2026 | 1.614B |
| September 22, 2026 | 1.663B |
| September 21, 2026 | 1.652B |
| September 18, 2026 | 1.612B |
| September 17, 2026 | 1.618B |
| September 16, 2026 | 1.582B |
| September 15, 2026 | 1.654B |
| September 14, 2026 | 1.677B |
| September 11, 2026 | 1.662B |
| September 10, 2026 | 1.719B |
| September 09, 2026 | 1.810B |
| September 08, 2026 | 1.819B |
| September 04, 2026 | 1.874B |
| September 03, 2026 | 1.885B |
| September 02, 2026 | 1.894B |
| September 01, 2026 | 1.833B |
| August 31, 2026 | 1.761B |
| August 28, 2026 | 1.784B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.735B |
| Emergent BioSolutions, Inc. | 647.68M |
| Incyte Corp. | 20.59B |
| Vertex Pharmaceuticals, Inc. | 138.87B |
| Travere Therapeutics, Inc. | 4.890B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.43M |
| Revenue (Quarterly) | 83.30M |
| Total Expenses (Quarterly) | 132.73M |
| EPS Diluted (Quarterly) | -0.5505 |
| Gross Profit Margin (Quarterly) | 83.19% |
| Profit Margin (Quarterly) | -59.34% |
| Earnings Yield | -24.81% |
| Normalized Earnings Yield | -24.81 |